Rafferty Asset Management
ESPR

Rafferty Asset Management’s Esperion Therapeutics ESPR Stock Holding History

Rafferty Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$200K Buy
63,262
+8,717
+16% +$24.4K ﹤0.01% 1110
2026
Q1 		$149K Sell
54,545
-6,500
-11% -$20.6K ﹤0.01% 1037
2025
Q4 		$226K Buy
61,045
+32,794
+116% +$106K ﹤0.01% 1067
2025
Q3 		$74.9K Buy
+28,251
New +$54.6K ﹤0.01% 1102
2025
Q2 		– Sell
-40,608
Closed -$58.5K – 1085
2025
Q1 		$58.5K Buy
40,608
+3,552
+10% +$6.54K ﹤0.01% 1054
2024
Q4 		$81.5K Buy
+37,056
New +$86.5K ﹤0.01% 1131
2023
Q2 		– Sell
-13,287
Closed -$21.1K – 1106
2023
Q1 		$21.1K Buy
13,287
+2,396
+22% +$12.4K ﹤0.01% 1138
2022
Q4 		$67.9K Buy
+10,891
New +$77.9K ﹤0.01% 1115
2022
Q1 		– Sell
-34,327
Closed -$172K – 1252
2021
Q4 		$172K Buy
+34,327
New +$275K ﹤0.01% 1237
2021
Q3 		– Sell
-98,918
Closed -$2.09M – 1278
2021
Q2 		$2.09M Sell
98,918
-10,897
-10% -$262K 0.01% 674
2021
Q1 		$3.08M Buy
109,815
+79,954
+268% +$2.36M 0.02% 471
2020
Q4 		$776K Sell
29,861
-22,575
-43% -$676K 0.01% 579
2020
Q3 		$1.95M Buy
52,436
+30,476
+139% +$1.21M 0.02% 424
2020
Q2 		$1.13M Buy
+21,960
New +$919K 0.02% 509
2020
Q1 		– Sell
-31,356
Closed -$1.87M – 668
2019
Q4 		$1.87M Sell
31,356
-63,078
-67% -$2.84M 0.03% 410
2019
Q3 		$3.46M Buy
94,434
+1,175
+1% +$46.5K 0.05% 203
2019
Q2 		$4.34M Buy
93,259
+24,489
+36% +$1.15M 0.08% 193
2019
Q1 		$2.76M Buy
+68,770
New +$3.08M 0.04% 252

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Rafferty Asset Management's ESPR Position: Q2 2026 in Review

Rafferty Asset Management increased its Esperion Therapeutics (ESPR) stake by 16% in Q2 2026, buying an estimated $24.4K and bringing the position to 63,262 shares worth $200K. The position accounts for ﹤0.01% of the portfolio, ranked #1110.

Rafferty Asset Management first reported a position in ESPR in Q1 2019 and has held it in 18 quarters since. The position peaked at $4.34M in Q2 2019. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Rafferty Asset Management held 63,262 shares of Esperion Therapeutics worth $200K as of Q2 2026.
  • Rafferty Asset Management bought 8,717 Esperion Therapeutics shares in Q2 2026, an estimated $24.4K.
  • Esperion Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #1110 holding.
  • Rafferty Asset Management first reported a position in Esperion Therapeutics in Q1 2019 and has held it in 18 quarters since.
  • Rafferty Asset Management's Esperion Therapeutics position peaked at $4.34M in Q2 2019.
  • 192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.